Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.33 Insider Own6.31% Shs Outstand82.32M Perf Week6.09%
Market Cap4.39B Forward P/E- EPS next Y-5.05 Insider Trans-2.93% Shs Float77.14M Perf Month20.88%
Income-606.64M PEG- EPS next Q-1.76 Inst Own104.64% Short Float4.61% Perf Quarter37.22%
Sales434.25M P/S10.11 EPS this Y22.67% Inst Trans-3.16% Short Ratio4.47 Perf Half Y44.90%
Book/sh3.35 P/B15.93 EPS next Y20.79% ROA-39.80% Short Interest3.56M Perf Year18.34%
Cash/sh7.03 P/C7.58 EPS next 5Y8.90% ROE-193.23% 52W Range31.52 - 54.98 Perf YTD11.48%
Dividend Est.- P/FCF- EPS past 5Y-15.75% ROI-51.92% 52W High-3.04% Beta0.66
Dividend TTM- Quick Ratio2.49 Sales past 5Y63.06% Gross Margin88.54% 52W Low69.13% ATR (14)2.05
Dividend Ex-Date- Current Ratio2.61 EPS Y/Y TTM17.65% Oper. Margin-131.08% RSI (14)65.90 Volatility4.69% 3.91%
Employees1276 Debt/Eq3.39 Sales Y/Y TTM19.52% Profit Margin-139.70% Recom1.30 Target Price89.85
Option/ShortYes / Yes LT Debt/Eq3.24 EPS Q/Q29.83% Payout- Rel Volume0.87 Prev Close53.69
Sales Surprise6.71% EPS Surprise10.98% Sales Q/Q23.27% EarningsFeb 15 AMC Avg Volume796.54K Price53.31
SMA2011.22% SMA5013.75% SMA20025.45% Trades Volume692,787 Change-0.71%
Date Action Analyst Rating Change Price Target Change
Dec-08-23Initiated Wells Fargo Overweight $72
Jun-14-23Resumed Credit Suisse Outperform $96
Jun-06-23Upgrade Evercore ISI In-line → Outperform $60 → $80
Apr-26-23Initiated Cantor Fitzgerald Overweight $114
Jan-18-23Resumed Canaccord Genuity Buy $90
Dec-30-22Resumed H.C. Wainwright Buy $82
Nov-03-22Upgrade Robert W. Baird Neutral → Outperform $50
Oct-13-22Upgrade Guggenheim Neutral → Buy $50
Aug-01-22Downgrade Evercore ISI Outperform → In-line $95 → $60
Mar-16-22Upgrade Credit Suisse Neutral → Outperform $99 → $105
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
04:15PM Loading…
Feb-15-24 04:15PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
Jan-09-24 06:20PM
12:18PM Loading…
Jan-08-24 12:18PM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
Dec-18-23 09:29AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
05:00PM Loading…
Nov-07-23 05:00PM
Nov-04-23 01:12PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
Oct-20-23 04:00PM
Oct-18-23 09:16PM
Oct-17-23 04:02PM
Oct-16-23 08:00AM
Oct-14-23 04:30PM
Oct-12-23 05:00PM
Oct-09-23 08:00AM
Oct-05-23 08:00AM
Sep-25-23 05:13PM
Sep-20-23 05:00PM
Sep-07-23 12:36PM
Aug-31-23 09:00AM
Aug-18-23 05:00PM
Aug-12-23 11:05AM
Aug-11-23 11:14AM
Aug-10-23 06:27PM
Aug-08-23 07:11AM
Aug-04-23 08:34AM
Aug-03-23 04:09PM
Jul-31-23 08:00AM
Jul-27-23 05:00PM
Jul-18-23 05:00PM
Jul-13-23 03:00PM
Jul-12-23 08:00AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
Jun-28-23 11:06AM
Jun-21-23 08:00AM
Jun-20-23 05:00PM
Jun-09-23 10:55AM
Jun-07-23 05:00PM
Jun-05-23 04:00PM
May-24-23 06:39AM
May-19-23 08:30AM
May-18-23 05:00PM
May-17-23 08:00AM
May-15-23 02:43PM
May-08-23 04:02PM
May-05-23 04:01PM
May-04-23 04:01PM
Apr-28-23 12:27PM
Apr-27-23 04:05PM
Apr-19-23 04:01PM
Apr-18-23 03:27PM
Mar-28-23 04:01PM
Mar-21-23 08:30AM
Mar-14-23 08:30AM
Feb-28-23 04:01PM
Feb-20-23 07:40AM
Feb-19-23 03:36PM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAKKIS EMIL DPresident & CEOFeb 07Sale45.0030,0001,350,000539,770Feb 08 03:49 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerJan 02Option Exercise21.003,00063,00027,892Jan 02 04:06 PM
KAKKIS EMIL DPresident & CEODec 29Sale47.8730,0001,436,100569,770Jan 02 04:07 PM
Kassberg Thomas RichardCBO & EVPOct 23Option Exercise6.8639,878273,563286,738Oct 24 05:22 PM
Kassberg Thomas RichardCBO & EVPOct 23Sale32.7839,8781,307,201246,860Oct 24 05:22 PM
KAKKIS EMIL DPresident & CEOOct 19Option Exercise6.8647,853328,272647,029Oct 23 05:14 PM
KAKKIS EMIL DPresident & CEOOct 19Sale33.5247,8531,604,033599,743Oct 23 05:14 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 07Option Exercise21.002,00042,00025,777Sep 11 01:52 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 07Sale40.802,16388,24923,614Sep 11 01:52 PM
Harris ErikEVP & Chief Commercial OfficerSep 05Sale37.966,000227,76051,281Sep 06 05:51 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 01Sale37.1597036,03223,777Sep 06 05:50 PM
Sanders Corazon (Corsee) D.DirectorJun 30Sale46.7658527,3558,985Jun 30 02:34 PM
Harris ErikEVP & Chief Commercial OfficerJun 19Sale48.2030514,70157,281Jun 21 06:17 PM
Sanders Corazon (Corsee) D.DirectorJun 08Sale51.651,48576,7009,570Jun 09 02:31 PM
Pinion John RichardSee RemarksMay 18Sale50.002,012100,60074,744May 19 01:54 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerMay 09Option Exercise21.003,00063,00030,747May 10 08:09 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMay 04Sale45.004,378197,01051,982May 05 02:16 PM